

ongoing trials - trial from [www.clinicaltrials.gov](http://www.clinicaltrials.gov)

# **A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX 121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age (VX21-121-105)**

**Code:**  
CTIS-2024-513754-29-00 **Year:** 2024 **Date:** December 30, 2023

**Author:**

## **Study design (if review, criteria of inclusion for studies)**

Interventional - Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment

## **Participants**

Cystic Fibrosis-related Diabetes|Cystic Fibrosis - 18 Years and older (Adult, Older Adult)

## **Interventions**

Drug: Empagliflozin|Other: Placebo Control

## **Outcome measures**

Feasibility, safety, tolerability

## **Keywords**

Empagliflozin; SGLT2 inhibitors; Hypoglycemic Agents; pharmacological\_intervention;